MONTREAL, March 10, 2005 (PRIMEZONE) -- Mr. Richard Lee, President of Viropro, Inc. (OTCBB:VPRO), is pleased to announce the appointment of Dr. Patrick Benoist as Director of the Biopharmaceutical Division of its subsidiary Viropro Pharma Inc.
Dr. Benoit will oversee all activities related to the identification and scientific validation of new recombinant proteins in addition to business development, planning and the set-up of technological transfers in International markets targeted by Viropro Pharma.
"I'm very happy to collaborate with the Company's scientific committee of six world-recognized doctors and scientists specialized in the field of molecular biotechnology, and to offer them the benefit of my scientific and business expertise," declared Dr. Benoist. "Our challenge is to ensure the development of a solid range of superior-quality bio-generic products that, combined with winning strategies, will allow us to sustain a favorable position on International markets and generate short-term revenue."
Dr. Benoist brings more than 20 years of solid experience as a researcher and project leader in the management and coordination of several research projects. As well, he boasts expertise in various fields of biology and in a wide range of scientific disciplines (molecular and cellular biology, biochemistry of proteins, plant biology, microscopy). His research activities have been mainly conducted with prestigious, internationally-renowned centers in France, Spain and Belgium. Within the frame of the mandates he has received, Dr. Benoist has also collaborated with private European companies in the development and validation of bio-processes, marketing kits and genetically modified organisms.
Dr. Benoist earned a Ph.D. in microbiology in 1992 from the Universite Paris 7. He also received a degree in operations management in 2004 from the CNAM of Toulouse, France.
About Viropro Inc.
Viropro, Inc. (OTCBB:VPRO) is establishing a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.
DIRECT ALL INQUIRIES TO TRIVOR FINANCIAL COMMUNICATIONS:
Georges Amar 514.731.5552 Extension 237 gamar@trivorgroup.com Jeff Morrisson 514.731.5552 Extension 225 jmorrisson@trivorgroup.com Helene Dupont 514.731.5552 Extension 285 hdupont@trivorgroup.com